PI: Mads H. Haugen
Numerous cancer drugs are not in use because we do not know which subgroup of patients obtains an adequate response. The mission of this project, which is supported by Kreftforeningen, is to develop diagnostic tools using expression of proteins and mRNA to reveal which patients could benefit from specific treatments. An important aspect is further to translate results from the laboratory into clinical use, so they can be of real benefit for the patients. Biomarkers at the proteomic level have been successfully used in clinical BC prognostics and diagnostics for decades (e.g. ER and Her2), primarily by means of immunehistochemistry (IHC). However, there is a practical limit in the number of markers that can be evaluated simultaneously, and future cancer diagnostics will likely also rely on information from signatures of multiple proteins simultaneously assessed.
In the NeoAva clinical trial we have developed a protein signature score by coupling protein expression in the tumor prior to treatment with tumor shrinkage during neoadjuvant treatment capable of predicting which BC patients that have a good response to treatment with bevacizumab in combination with chemotherapy. We are currently in the process of adapting use of this protein signature to the clinically usable platform NanoString.